Totem ( the startup behind the first widely adopted peer-to-peer navigation device designed to work entirely without cellular service, today announced Version 4.1 of the Totem Compass and a newly ...

Don't underestimate Samsung's handy side-swipe menu ...

Furthering your education locally is easy, with a wide range of training opportunities offered by schools and organisations island-wide.

Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...

The Brookfield-owned hyperscale developer is planning to issue asset-backed securities backed by six new, fully leased data centers in Phoenix and Toronto, according to a presale report from Moody’s ...

The American Depositary Shares ("ADS") of the United Kingdom-based biotech Compass Pathways plc (CMPS) are soaring today, after management announced its psychedelic drug candidate COMP006 had met the ...

Compass’ fourth-quarter earnings call this week came with more than bottom-line metrics.  The company announced a three-year partnership with Rocket and Redfin. The “strategic alliance,” as Compass ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Good morning. I’ve fallen ...

The global law enforcement crackdown, which began in January 2025, also identified nearly 180 members of the notorious ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ...

Compass CEO and co-founder Robert Reffkin and Rocket CEO Varun Krishna join 'Squawk Box' to discuss details of their strategic alliance to increase home listing inventory on Redfin, tackling home ...

Investing.com - Canaccord Genuity raised its price target on Compass Therapeutics (NASDAQ:CMPX) to $13.00 from $10.00 on Wednesday, while maintaining a Buy rating on the stock. The new target ...